A medication that stops Alzheimer's in its tracks?

Share this article:

Baxter BioScience's Gammagard halted the progression of Alzheimer's disease for as long as three years in a 16-patient trial. Results were presented at the Alzheimer's Association's annual meeting in Vancouver. The findings offer a “tantalizing” glimpse of the drug's potential, said William Thies, the association's chief medical and scientific officer.

A definitive study of 390 patients will be completed this year and released in early 2013, said Norman Relkin, the lead researcher, and the director of the Memory Disorders Program and a neurologist at New York Presbyterian/Weill Cornell Medical Center.

Share this article:
close

Next Article in Products

More in Products

Malnutrition remains issue

Identifying malnutrition in patients upon admission to a hospital is a low-cost way to improve patient outcomes and reduce readmissions, a new report says. Alleviating Hospital-Based Malnutrition: A Baseline Progress Report is an assessment of hospital-based malnutrition released in connection with the first anniversary of ...

Construction Specialties introduces wall and door protection

Construction Specialties introduces wall and door protection

Construction Specialties Inc. (C/S) has debuted a new line of wall and door protection, Acrovyn by Design and Acrovyn Doors by Design. The products embed high-resolution images and logos as ...

BioSensics launches ActivePERS fall detection

BioSensics launches ActivePERS fall detection

BioSensics has introduced ActivePERS, a personal emergency response and telemonitoring solution for seniors.